OncRef

Clinical Trial: NCT04473911

Haplo Peripheral Blood Sct In GVHD Prevention

Status:

COMPLETED

Phase:

Phase 1

Lead Sponsor:Zachariah Michael DeFilipp
Information Provided By:Massachusetts General Hospital
Last Update Posted:2025-07-20

Study Overview

Brief Summary

This research study is studying the RGI-2001 for preventing Graft-vs-Host Disease (GVHD) in people with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), myeloproliferative disorders (MPN), chronic myelomonocytic leukemic (CMML), chemosensitive hodgkin lymphoma (HL), or Non-Hodgkin lymphoma (NHL).who will have a blood stem cell transplantation.

  • GVHD is a condition in which cells from the donor's tissue attack the organs.
  • RGI-2001 is an investigational treatment

Official Title

Reduced Intensity Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Sirolimus/Mycophenolate Mofetil/RGI-2001 Based GVHD Prevention: a Pilot Study

Conditions

GVHD, AML, ALL, MDS, MPN, CMML, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Blood Stem Cell Transplant Failure, Graft Vs Host Disease, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorder, Chronic Myelomonocytic Leukemia, Chemosensitive Hodgkin Lymphoma

Intervention / Treatment

  • Drug: FLUDARABINE
  • Drug: CYCLOPHOSPHAMIDE
  • Radiation: TBI
  • Drug: Melphalan
  • Drug: Sirolimus
  • Drug: Mycophenolate mofetil
  • Drug: RGI-2001
  • Drug: CYCLOPHOSPHAMIDE

Other Study ID Numbers

  • 19-336

Start Date (Actual)

2020-08-14

Primary Completion Date (Actual)

2023-10-22

Study Completion Date (Actual)

2024-08-19

Enrollment (Actual)

25

Study Type

Interventional

Phase

Phase 1